

# Statistical Report (Overview)

## Created on September 30, 2025

\*The preliminary data are tentatively compiled figures based on the JPO Statistical Database.  
Please be noted that the data may be subject to change through continual data collection and processing.

### (1) The Number of Applications

| Year/ Month              |                       | 2025<br>6        | 7                | 2025/1-7<br>(Cum Sum<br>of 2025) | 2024/1-7<br>(Year-on-Year) | 2025/4 - 7<br>(Cum Sum<br>of FY2025) | 2024/4 - 7<br>(Year-on-Year) | Q1 of FY2025     | 2024/4 - 2025/3<br>(Total of FY2024) |
|--------------------------|-----------------------|------------------|------------------|----------------------------------|----------------------------|--------------------------------------|------------------------------|------------------|--------------------------------------|
| Patents & Utility Models |                       | 27,141<br>(14.8) | 23,935<br>(▲8.1) | 174,025<br>(1.3)                 | 171,765<br>(▲0.2)          | 95,457<br>(0.9)                      | 94,584<br>(1.8)              | 71,522<br>(4.4)  | 312,897<br>(3.2)                     |
|                          | Patents               | 26,731<br>(15.0) | 23,468<br>(▲8.4) | 171,286<br>(1.3)                 | 169,037<br>(▲0.1)          | 93,786<br>(0.9)                      | 92,954<br>(2.0)              | 70,318<br>(4.4)  | 308,272<br>(3.4)                     |
|                          | Utility Models        | 410<br>(6.8)     | 467<br>(6.4)     | 2,739<br>(0.4)                   | 2,728<br>(▲6.0)            | 1,671<br>(2.5)                       | 1,630<br>(▲7.3)              | 1,204<br>(1.1)   | 4,625<br>(▲5.7)                      |
| Designs                  |                       | 2,679<br>(▲2.2)  | 2,625<br>(▲8.9)  | 18,367<br>(▲0.8)                 | 18,524<br>(3.4)            | 10,489<br>(▲2.8)                     | 10,792<br>(6.9)              | 7,864<br>(▲0.6)  | 32,211<br>(1.8)                      |
|                          | National Applications | 2,262<br>(▲4.2)  | 2,254<br>(▲8.7)  | 15,389<br>(▲4.1)                 | 16,041<br>(1.7)            | 8,706<br>(▲5.5)                      | 9,211<br>(4.1)               | 6,452<br>(▲4.3)  | 27,400<br>(▲0.3)                     |
| Trademarks               |                       | 14,827<br>(12.0) | 15,607<br>(10.0) | 98,253<br>(5.8)                  | 92,849<br>(▲3.7)           | 58,759<br>(7.6)                      | 54,599<br>(▲1.6)             | 43,152<br>(6.8)  | 160,036<br>(▲0.8)                    |
|                          | National Applications | 13,675<br>(14.9) | 14,059<br>(9.4)  | 88,630<br>(5.2)                  | 84,253<br>(▲2.1)           | 53,305<br>(7.5)                      | 49,585<br>(▲0.8)             | 39,246<br>(6.8)  | 143,197<br>(▲1.4)                    |
| Total Number             |                       | 44,647<br>(12.7) | 42,167<br>(▲2.2) | 290,645<br>(2.7)                 | 283,138<br>(▲1.1)          | 164,705<br>(3.0)                     | 159,975<br>(0.9)             | 122,538<br>(4.9) | 505,144<br>(1.8)                     |
| Trademark Class Counts   |                       | 26,709<br>(17.8) | 26,429<br>(6.9)  | 171,567<br>(3.8)                 | 165,252<br>(▲3.6)          | 101,637<br>(5.8)                     | 96,030<br>(▲1.3)             | 75,208<br>(5.5)  | 279,163<br>(▲2.9)                    |

### (2) The Number of International Applications

| Year/ Month        |    | 2025<br>6        | 7               | 2025/1-7<br>(Cum Sum<br>of 2025) | 2024/1-7<br>(Year-on-Year) | 2025/4 - 7<br>(Cum Sum<br>of FY2025) | 2024/4 - 7<br>(Year-on-Year) | Q1 of FY2025     | 2024/4 - 2025/3<br>(Total of FY2024) |
|--------------------|----|------------------|-----------------|----------------------------------|----------------------------|--------------------------------------|------------------------------|------------------|--------------------------------------|
| P<br>C<br>T        | RO | 3,811<br>(6.3)   | 3,724<br>(▲1.8) | 27,394<br>(▲0.7)                 | 27,585<br>(▲1.6)           | 14,030<br>(▲0.8)                     | 14,146<br>(▲1.0)             | 10,306<br>(▲0.5) | 46,676<br>(▲0.8)                     |
|                    | DO | 6,982<br>(1.2)   | 5,651<br>(▲5.1) | 41,940<br>(▲3.0)                 | 43,227<br>(▲1.4)           | 24,811<br>(▲3.5)                     | 25,704<br>(0.6)              | 19,160<br>(▲3.0) | 72,707<br>(▲3.2)                     |
| Hague<br>Agreement | OA | 1<br>(0.0)       | 1<br>(0.0)      | 4<br>(▲42.9)                     | 7<br>(40.0)                | 2<br>(▲50.0)                         | 4<br>(▲20.0)                 | 1<br>(▲75.0)     | 9<br>(0.0)                           |
|                    | DO | 417<br>(10.3)    | 371<br>(▲10.0)  | 2,978<br>(19.9)                  | 2,483<br>(15.6)            | 1,783<br>(12.8)                      | 1,581<br>(27.0)              | 1,412<br>(20.8)  | 4,811<br>(15.6)                      |
| Madrid<br>Protocol | OO | 273<br>(19.7)    | 237<br>(▲4.0)   | 1,782<br>(7.7)                   | 1,654<br>(11.2)            | 972<br>(9.2)                         | 890<br>(11.1)                | 735<br>(14.3)    | 3,062<br>(4.8)                       |
|                    | DO | 1,152<br>(▲13.8) | 1,548<br>(16.0) | 9,623<br>(11.9)                  | 8,596<br>(▲16.7)           | 5,454<br>(8.8)                       | 5,014<br>(▲9.5)              | 3,906<br>(6.2)   | 16,839<br>(3.9)                      |

### (3) The Number of Requests for Patent Examination and Report of Utility Model Technical Opinion

| Year/ Month                               |              | 2025<br>6        | 7                | 2025/1-7<br>(Cum Sum<br>of 2025) | 2024/1-7<br>(Year-on-Year) | 2025/4 - 7<br>(Cum Sum<br>of FY2025) | 2024/4 - 7<br>(Year-on-Year) | Q1 of FY2025    | 2024/4 - 2025/3<br>(Total of FY2024) |
|-------------------------------------------|--------------|------------------|------------------|----------------------------------|----------------------------|--------------------------------------|------------------------------|-----------------|--------------------------------------|
| Request for Patent Examination            |              | 19,922<br>(4.0)  | 18,394<br>(▲3.2) | 133,354<br>(▲1.4)                | 135,258<br>(0.6)           | 73,864<br>(▲0.2)                     | 74,030<br>(1.0)              | 55,470<br>(0.8) | 226,718<br>(▲1.5)                    |
|                                           | Year-on-Year | 19,153<br>(▲3.4) | 19,008<br>(▲0.5) | —<br>—                           | —<br>—                     | —<br>—                               | —<br>—                       | —<br>—          | —<br>—                               |
| Report of Utility Model Technical Opinion |              | 10<br>(0.0)      | 11<br>(▲35.3)    | 88<br>(▲5.4)                     | 93<br>(▲20.5)              | 45<br>(▲21.1)                        | 57<br>(▲12.3)                | 34<br>(▲15.0)   | 155<br>(▲15.3)                       |

#### (4) The Number of Requests for Trials and Appeals

| Year/ Month |                                                   | 2025<br>6      | 7              | 2025/1-7<br>(Cum Sum<br>of 2025) | 2024/1-7<br>(Year-on-Year) | 2025/4 - 7<br>(Cum Sum<br>of FY2025) | 2024/4 - 7<br>(Year-on-Year) | Q1 of FY2025    | 2024/4 - 2025/3<br>(Total of FY2024) |
|-------------|---------------------------------------------------|----------------|----------------|----------------------------------|----------------------------|--------------------------------------|------------------------------|-----------------|--------------------------------------|
| Patents     | Appeals against Examiner's<br>Decision of Refusal | 1,648<br>(5.7) | 1,719<br>(3.7) | 11,289<br>(▲5.0)                 | 11,887<br>(▲0.6)           | 6,707<br>(▲1.0)                      | 6,777<br>(▲4.6)              | 4,988<br>(▲2.6) | 19,540<br>(▲8.3)                     |
|             | Trials for Invalidation                           | 13<br>(116.7)  | 8<br>(▲55.6)   | 62<br>(▲37.4)                    | 99<br>(102.0)              | 43<br>(▲15.7)                        | 51<br>(82.1)                 | 35<br>(6.1)     | 157<br>(41.4)                        |
|             | Trials for Correction                             | 10<br>(▲44.4)  | 23<br>(53.3)   | 99<br>(20.7)                     | 82<br>(▲18.8)              | 70<br>(25.0)                         | 56<br>(▲15.2)                | 47<br>(14.6)    | 169<br>(22.5)                        |
|             | Hantei (Advisory Opinion)                         | 0<br>(▲100.0)  | 3<br>(50.0)    | 7<br>(▲63.2)                     | 19<br>(26.7)               | 4<br>(▲73.3)                         | 15<br>(200.0)                | 1<br>(▲92.3)    | 28<br>(▲15.2)                        |
|             | oppositions                                       | 115<br>(7.5)   | 129<br>(2.4)   | 818<br>(2.9)                     | 795<br>(▲7.8)              | 467<br>(▲2.1)                        | 477<br>(▲3.4)                | 338<br>(▲3.7)   | 1,428<br>(▲5.0)                      |
|             | Total                                             | 1,786<br>(5.3) | 1,882<br>(3.5) | 12,275<br>(▲4.7)                 | 12,882<br>(▲0.8)           | 7,291<br>(▲1.2)                      | 7,376<br>(▲4.2)              | 5,409<br>(▲2.7) | 21,322<br>(▲7.6)                     |

| Year/ Month    |                                                   | 2025<br>6     | 7            | 2025/1-7<br>(Cum Sum<br>of 2025) | 2024/1-7<br>(Year-on-Year) | 2025/4 - 7<br>(Cum Sum<br>of FY2025) | 2024/4 - 7<br>(Year-on-Year) | Q1 of FY2025 | 2024/4 - 2025/3<br>(Total of FY2024) |
|----------------|---------------------------------------------------|---------------|--------------|----------------------------------|----------------------------|--------------------------------------|------------------------------|--------------|--------------------------------------|
| Utility Models | Appeals against Examiner's<br>Decision of Refusal | 0<br>(0.0)    | 0<br>(0.0)   | 0<br>(0.0)                       | 0<br>(0.0)                 | 0<br>(0.0)                           | 0<br>(0.0)                   | 0<br>(0.0)   | 0<br>(0.0)                           |
|                | Trials for Invalidation                           | 0<br>(▲100.0) | 2<br>(100.0) | 5<br>(66.7)                      | 3<br>(0.0)                 | 3<br>(50.0)                          | 2<br>(0.0)                   | 1<br>(0.0)   | 7<br>(600.0)                         |
|                | Trials for Correction                             | 0<br>(0.0)    | 0<br>(0.0)   | 0<br>(0.0)                       | 0<br>(0.0)                 | 0<br>(0.0)                           | 0<br>(0.0)                   | 0<br>(0.0)   | 0<br>(0.0)                           |
|                | Hantei (Advisory Opinion)                         | 1<br>(0.0)    | 0<br>(0.0)   | 1<br>(0.0)                       | 0<br>(0.0)                 | 1<br>(0.0)                           | 0<br>(0.0)                   | 1<br>(0.0)   | 0<br>(0.0)                           |
|                | Total                                             | 1<br>(0.0)    | 2<br>(100.0) | 6<br>(100.0)                     | 3<br>(0.0)                 | 4<br>(100.0)                         | 2<br>(0.0)                   | 2<br>(100.0) | 7<br>(600.0)                         |

| Year/ Month |                                                   | 2025<br>6     | 7             | 2025/1-7<br>(Cum Sum<br>of 2025) | 2024/1-7<br>(Year-on-Year) | 2025/4 - 7<br>(Cum Sum<br>of FY2025) | 2024/4 - 7<br>(Year-on-Year) | Q1 of FY2025  | 2024/4 - 2025/3<br>(Total of FY2024) |
|-------------|---------------------------------------------------|---------------|---------------|----------------------------------|----------------------------|--------------------------------------|------------------------------|---------------|--------------------------------------|
| Designs     | Appeals against Examiner's<br>Decision of Refusal | 29<br>(▲14.7) | 54<br>(157.1) | 215<br>(25.0)                    | 172<br>(▲7.5)              | 126<br>(23.5)                        | 102<br>(▲1.9)                | 72<br>(▲11.1) | 299<br>(▲4.8)                        |
|             | Trials for Invalidation                           | 0<br>(▲100.0) | 0<br>(0.0)    | 5<br>(0.0)                       | 5<br>(▲16.7)               | 4<br>(100.0)                         | 2<br>(100.0)                 | 4<br>(100.0)  | 6<br>(▲25.0)                         |
|             | Hantei (Advisory Opinion)                         | 1<br>(0.0)    | 2<br>(0.0)    | 10<br>(11.1)                     | 9<br>(50.0)                | 5<br>(25.0)                          | 4<br>(0.0)                   | 3<br>(▲25.0)  | 11<br>(▲15.4)                        |
|             | Total                                             | 30<br>(▲16.7) | 56<br>(166.7) | 230<br>(23.7)                    | 186<br>(▲6.1)              | 135<br>(25.0)                        | 108<br>(▲0.9)                | 79<br>(▲9.2)  | 316<br>(▲5.7)                        |

| Year/ Month |                                                   | 2025<br>6     | 7             | 2025/1-7<br>(Cum Sum<br>of 2025) | 2024/1-7<br>(Year-on-Year) | 2025/4 - 7<br>(Cum Sum<br>of FY2025) | 2024/4 - 7<br>(Year-on-Year) | Q1 of FY2025  | 2024/4 - 2025/3<br>(Total of FY2024) |
|-------------|---------------------------------------------------|---------------|---------------|----------------------------------|----------------------------|--------------------------------------|------------------------------|---------------|--------------------------------------|
| Trademarks  | Appeals against Examiner's<br>Decision of Refusal | 108<br>(17.4) | 78<br>(4.0)   | 567<br>(6.4)                     | 533<br>(▲26.9)             | 345<br>(1.8)                         | 339<br>(▲15.0)               | 267<br>(1.1)  | 883<br>(▲8.9)                        |
|             | Trials for Invalidation                           | 6<br>(▲14.3)  | 9<br>(0.0)    | 42<br>(▲4.5)                     | 44<br>(▲29.0)              | 29<br>(3.6)                          | 28<br>(▲3.4)                 | 20<br>(5.3)   | 83<br>(6.4)                          |
|             | Trials for Cancellation                           | 91<br>(4.6)   | 114<br>(3.6)  | 636<br>(9.8)                     | 579<br>(▲2.5)              | 356<br>(▲0.8)                        | 359<br>(0.0)                 | 242<br>(▲2.8) | 1,148<br>(13.2)                      |
|             | Hantei (Advisory Opinion)                         | 1<br>(0.0)    | 1<br>(0.0)    | 5<br>(0.0)                       | 5<br>(▲58.3)               | 3<br>(0.0)                           | 3<br>(▲72.7)                 | 2<br>(▲33.3)  | 8<br>(▲50.0)                         |
|             | Oppositions                                       | 25<br>(47.1)  | 23<br>(▲11.5) | 176<br>(1.7)                     | 173<br>(▲5.5)              | 101<br>(13.5)                        | 89<br>(▲17.6)                | 78<br>(23.8)  | 285<br>(▲12.3)                       |
|             | Total                                             | 231<br>(13.2) | 225<br>(2.3)  | 1,426<br>(6.9)                   | 1,334<br>(▲15.6)           | 834<br>(2.0)                         | 818<br>(▲9.7)                | 609<br>(1.8)  | 2,407<br>(0.2)                       |